Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Beta Finch - Vertex Pharma - VRTX - EN cover art

Beta Finch - Vertex Pharma - VRTX - EN

Beta Finch - Vertex Pharma - VRTX - EN

Written by: Beta Finch
Listen for free

About this listen
AI-powered earnings call analysis for Vertex Pharmaceuticals (VRTX). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Vertex Pharmaceuticals Q3 2026 Earnings Analysis
    Nov 3 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' third quarter 2026 results, and this one is packed with news. I'm Alex.

    **JORDAN:** And I'm Jordan. Vertex is quietly transforming from a cystic fibrosis company into something much bigger, and this quarter really drives that home.

    **ALEX:** Before we jump in, quick reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Alright, let's get into the numbers.

    **ALEX:** Vertex posted 12% year-over-year revenue growth in Q3, with 10% growth domestically and 16% internationally. That's a nicely balanced global story. And they raised full-year guidance to a range of $13.15 billion to $13.25 billion.

    **JORDAN:** What stood out to me is *where* that growth is coming from. Yes, cystic fibrosis is still the backbone—$3.3 billion in the quarter, up 8%—but the real excitement is in the newer stuff. CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, hit $99 million, up 30% sequentially. And JOURNAVX, the non-opioid pain medicine, brought in $58 million with over 750,000 prescriptions in the quarter alone.

    **ALEX:** JOURNAVX is actually now the number one prescribed branded oral analgesic in the U.S. That's a big milestone for a drug that's trying to change decades of prescribing habits around pain management.

    **JORDAN:** Right, and management is playing a long game there. They're keeping a patient support program running through 2027 to make sure patients get access even before insurance fully catches up. That's actually suppressing reported revenue right now because of gross-to-net dynamics, but it sets up for a cleaner growth trajectory once that program sunsets.

    **ALEX:** Now here's the headline strategic move: Vertex closed its $9 billion acquisition of Crinetics Pharmaceuticals, which gives them Palsonify, an oral treatment for acromegaly. This is officially their fourth commercial pillar, and management says they're on the verge of a fifth—renal medicine—pending a PDUFA decision on povitacept for IgA nephropathy on November 30th. That's just weeks away.

    **JORDAN:** That's the part I find most interesting. Vertex is essentially building a five-pillar company in real time—CF, hematology, pain, rare endocrine, and soon renal. Palsonify only contributed for one month post-close but still brought in $10 million in September alone, and full Q3 contribution was about $24 million. Early metrics look healthy too—roughly 500 endocrinologists are already writing prescriptions, with leading market share among new and switching patients.

    **ALEX:** On the earnings side, non-GAAP net income came in at $1.21 billion, or $4.76 per share. Gross margin was strong at 85.6% on a non-GAAP basis. But operating expenses are climbing—they revised full-year opex guidance up to approximately $6 billion, largely to absorb Crinetics integration costs and continued commercial scale-up for these launches.

    **JORDAN:** That's the trade-off here. Vertex is spending aggressively to support five simultaneous launches and a major acquisition integration. SG&A was up 51% year-over-year in the quarter, with most of that going toward commercial infrastructure for povitacept, JOURNAVX, and Palsonify.

    **ALEX:** Let's talk about the Q&A, because there were some meaty exchanges. Analysts pushed hard on povitacept—there was even a citizen's petition raising questions about IgG monitoring requirements. CEO Reshma Kewalramani addressed it head-on, noting that serious infection rates were balanced between drug and placebo arms in their trial, and that everything happening with the FDA review is proceeding a

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
  • Vertex Pharmaceuticals Q2 2026 Earnings Analysis
    Aug 29 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Alright, Alex, let's start with the headline numbers because they're pretty solid.

    ALEX: Yeah, Vertex posted $3.3 billion in total revenue for Q2, up 12% year-over-year. That's driven largely by the cystic fibrosis franchise, which grew 11%, but also some real acceleration from the newer products.

    JORDAN: Right, and this is the part I find genuinely interesting — CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, brought in $76 million this quarter. That's roughly 75% sequential growth and over 150% year-over-year. They had more infusions in the first half of 2026 than in all of 2025 combined.

    ALEX: That's a huge inflection point. And it's not slowing down either — they had over 100 patient initiations for a third straight quarter, plus a pediatric approval for ages two to eleven that came through in just 53 days post-filing.

    JORDAN: Then there's JOURNAVX, their non-opioid pain drug, at $50 million in revenue — about 70% sequential growth. The prescription numbers are climbing fast too, roughly 535,000 scripts this quarter. But here's the nuance: gross-to-net is still messy because of a patient support program covering people whose insurance has restrictions like quantity limits.

    ALEX: Management said that normalizes more toward branded-drug norms in the first half of 2027, so investors watching margins on JOURNAVX should expect some lumpiness for a few more quarters.

    JORDAN: On profitability — non-GAAP EPS came in at $4.73, up 5% year-over-year. Gross margin was 85.6%, a slight step down from Q1, which they attributed to product mix as CASGEVY, which costs more to manufacture, becomes a bigger slice of revenue.

    ALEX: And they raised full-year revenue guidance to $13.1 to $13.2 billion, reiterating that $500 million-plus target for non-CF revenue this year.

    JORDAN: Now let's talk about the big strategic move — the Crinetics Pharmaceuticals acquisition. This is roughly an $8.8 billion deal, expected to close in Q3.

    ALEX: This is Vertex adding a fifth commercial pillar — rare endocrine diseases like acromegaly, CAH, and Cushing's syndrome. The two lead assets from Crinetics, paltusotine and atumelnant, are pegged at a combined peak sales opportunity of about $5 billion.

    JORDAN: It's being funded through cash on hand plus a $4.5 billion term loan, and management said it should become accretive to operating income in 2029 — so this is a multi-year bet, not an immediate earnings boost.

    ALEX: Let's talk pipeline, because there's a lot moving. The renal franchise is arguably the most important near-term catalyst — povetacicept, or "Povi," for IgA nephropathy has an FDA decision date of November 30th after a really strong phase III interim analysis.

    JORDAN: And on the call, Reshma Kewalramani, the CEO, made a pretty confident case for Povi's differentiation — she cited a 52% reduction in proteinuria, which she called numerically the best in class, plus once-monthly dosing via a small-volume auto-injector patients can use at home.

    ALEX: There was also a great analyst question about how Vertex sees eGFR data compare against a competitor's recently published numbers. Reshma's answer was essentially: strong proteinuria reduction should translate to GFR stabilization, and Vertex believes Povi's numbers on proteinuria, hematuria, and other biomarkers

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Vertex Pharmaceuticals Q1 2026 Earnings Analysis
    May 5 2026
    **Beta Finch Podcast Script**

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex Pharmaceuticals' Q1 2026 earnings call - and wow, Jordan, this was packed with updates.

    JORDAN: Absolutely, Alex. But before we jump in, let me get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Thanks, Jordan. Now, let's talk Vertex. This biotech giant just delivered some impressive numbers - $2.99 billion in total revenue for Q1, representing 8% growth year-over-year. But what really caught my attention was how they're diversifying beyond their cystic fibrosis cash cow.

    JORDAN: Right, and that diversification story is really the headline here. CEO Reshma Kewalramani emphasized that their newer products - KASJEVY and GERNAVICS - drove about 25% of their total revenue growth. That's a company successfully expanding its footprint beyond a single therapeutic area.

    ALEX: Let's break down those newer products. KASJEVY, their gene editing therapy, brought in $43 million in Q1 revenue with over 500 patients now having started treatment. Then there's GERNAVICS for pain management at $29 million in revenue. But the real excitement seems to be around their renal pipeline, particularly something called Povitacicept or "Povi."

    JORDAN: Oh, the Povi data was genuinely impressive, Alex. They just completed what Kewalramani called their fastest regulatory submission in company history - 27 days from database lock to filing. The Phase III interim results for IgA nephropathy showed a 52% reduction in proteinuria, which is a key marker doctors watch. Kewalramani described the results as "sparkling from top to bottom."

    ALEX: And they're not stopping there with renal disease. They're positioning this as potentially their fourth major franchise alongside CF, blood disorders, and pain. The addressable patient population across their renal programs could be in the hundreds of thousands when you add up all the different kidney diseases they're targeting.

    JORDAN: What I found interesting in the Q&A was when analyst Jessica Fye asked about renal potentially rivaling their CF business in size. Kewalramani didn't shy away from that comparison. She pointed out that while each kidney disease is rare, they're "common rare diseases" - IgA nephropathy alone affects about 150,000 patients in North America and Europe.

    ALEX: The numbers definitely support the growth story. Non-GAAP earnings per share came in at $4.47, up from $4.06 the previous year. They're managing expenses well while investing heavily in these new areas - SG&A expenses were up 30% year-over-year, but that's driven by commercial investments in pain and renal programs.

    JORDAN: Speaking of investments, they spent about $344 million buying back shares in Q1, showing they're returning cash to shareholders while still funding growth. They ended the quarter with $13 billion in cash and investments, so they've got plenty of firepower.

    ALEX: Now, it wasn't all good news. They had to discontinue their VX-522 program for CF patients who can't benefit from their current modulators. Kewalramani explained they couldn't overcome tolerability issues related to lung inflammation, likely from the delivery mechanism.

    JORDAN: That's about 5,000 patients who still can't be helped by Vertex's current CF portfolio. But Kewalramani was adamant they're not giving up on this population. She said their "commitment to CF is absolute and steadfast" and they'll go back to the drawing board on delivery methods.

    ALEX: Let's talk guidance. They're sticking with their full-year revenue guidance of $12.95 to $13.10 billion, repre

    This episode includes AI-generated content.
    Show More Show Less
    9 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet